Sermorelin

A 29-amino acid GHRH analog representing the shortest fully functional fragment of native GHRH. It was previously FDA-approved for diagnosing and treating GH deficiency in children before being discontinued for commercial reasons.

• Binds GHRH receptors on anterior pituitary somatotrophs to stimulate GH synthesis and secretion
• Preserves the natural negative feedback loop of the GH-IGF-1 axis
• Promotes GH release that follows the endogenous pulsatile pattern

• Active malignancy
• Hypersensitivity to sermorelin or mannitol
• Pregnancy or breastfeeding
• Obesity-related GH suppression may reduce efficacy

Store unreconstituted vials at 2–8°C (36–46°F). Once reconstituted, refrigerate and use within 14 days. Do not freeze reconstituted solution.

Sermorelin was FDA-approved in 1997 under the brand name Geref for pediatric GH deficiency diagnosis and treatment. Clinical trials demonstrated its ability to restore physiologic GH secretion patterns. It was voluntarily withdrawn from market in 2008 for commercial reasons, not safety concerns, and remains available through compounding pharmacies.